WT1 Vaccine Helped High-Risk Multiple Myeloma Patients After Stem Cell Transplant
High-risk multiple myeloma patients may benefit markedly from galinpepimut-S, an experimental immunotherapy from SELLAS Life Sciences, following autologous stem cell transplant (ASCT), according to recent…